Biosolution Co Ltd
086820
Company Profile
Business description
Biosolution Co Ltd is a Korean company offering Cell-Based Biotechnology. It is engaged in manufacturing and selling cell therapy products, and developing cell therapeutics technology. Its main areas include cell-based therapeutics with their background in somatic and stem cell technology, and the manufacturing, sales, and R&D of human tissue models for screening toxicity and efficacy with tissue engineering technology.
Contact
Gongneung-Ro 232, Nowon-gu
5th Floor, Room 519, Seoul Technopark
Seoul
KORT: +82 234468884
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
100
Stocks News & Analysis
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks
This US AI winner has been unstoppable. Is it time to sell?
Astonishing results have driven this AI stock into significantly overvalued territory.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,855.90 | 79.60 | -0.89% |
| CAC 40 | 8,178.68 | 39.56 | -0.48% |
| DAX 40 | 24,620.35 | 138.70 | -0.56% |
| Dow JONES (US) | 50,866.78 | 695.15 | -1.35% |
| FTSE 100 | 10,364.16 | 3.89 | -0.04% |
| HKSE | 24,657.06 | 304.89 | -1.22% |
| NASDAQ | 25,709.43 | 1,121.53 | -4.18% |
| Nikkei 225 | 64,024.60 | 2,563.52 | -3.85% |
| NZX 50 Index | 13,038.24 | 123.73 | -0.94% |
| S&P 500 | 7,383.74 | 200.57 | -2.64% |
| S&P/ASX 200 | 8,625.10 | 80.00 | -0.92% |
| SSE Composite Index | 3,959.34 | 68.40 | -1.70% |